Buonerba C - Search Results

1

Penile cancer: current therapy and future directions.

Sonpavde G, Pagliaro LC, Buonerba C, Dorff TB, Lee RJ, Di Lorenzo G. Sonpavde G, et al. Among authors: buonerba c. Ann Oncol. 2013 May;24(5):1179-89. doi: 10.1093/annonc/mds635. Epub 2013 Jan 4. Ann Oncol. 2013. PMID: 23293117 Free PMC article. Review.

2

Ten-year adjuvant treatment with somatostatin analogs in a patient with atypical carcinoid of the lung.

Buonerba C, Gallo C, Di Lorenzo G, Romeo V, Marinelli A. Buonerba C, et al. Anticancer Drugs. 2010 Apr;21(4):465-8. doi: 10.1097/CAD.0b013e32833688a2. Anticancer Drugs. 2010. PMID: 20075713

3

Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer.

Riccardi F, Di Lorenzo G, Buonerba C, Monaco G, Monaco R, Rizzo M, Scagliarini S, Scognamiglio F, Di Napoli M, Carteni' G. Riccardi F, et al. Among authors: buonerba c. World J Surg Oncol. 2010 Feb 5;8:8. doi: 10.1186/1477-7819-8-8. World J Surg Oncol. 2010. PMID: 20137082 Free PMC article.

4

Castration-resistant prostate cancer: current and emerging treatment strategies.

Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Sternberg CN. Di Lorenzo G, et al. Among authors: buonerba c. Drugs. 2010 May 28;70(8):983-1000. doi: 10.2165/10898600-000000000-00000. Drugs. 2010. PMID: 20481655 Review.

5

Efficacy of rituximab in gastric diffuse large B cell lymphoma patients.

Leopardo D, Di Lorenzo G, De Renzo A, Federico P, Luponio S, Buonerba C, Matano E, Merola G, Imbimbo M, Montesarchio E, Rea A, Merola MC, De Placido S, Palmieri G. Leopardo D, et al. Among authors: buonerba c. World J Gastroenterol. 2010 May 28;16(20):2526-30. doi: 10.3748/wjg.v16.i20.2526. World J Gastroenterol. 2010. PMID: 20503452 Free PMC article.

6

Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?

Gallo C, Buonerba C, Di Lorenzo G, Romeo V, De Placido S, Marinelli A. Gallo C, et al. Among authors: buonerba c. J Neurooncol. 2010 Nov;100(2):311-9. doi: 10.1007/s11060-010-0168-y. Epub 2010 Jun 17. J Neurooncol. 2010. PMID: 20556481

7

Docetaxel rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice.

Buonerba C, Palmieri G, Di Lorenzo G. Buonerba C, et al. Eur Urol. 2010 Oct;58(4):636-7. doi: 10.1016/j.eururo.2010.06.025. Epub 2010 Jun 23. Eur Urol. 2010. PMID: 20580484 No abstract available.

8

Kidney cancer: overall survival is an unsuitable primary end point.

Di Lorenzo G, Buonerba C. Di Lorenzo G, et al. Among authors: buonerba c. Nat Rev Urol. 2010 Jul;7(7):367-8. doi: 10.1038/nrurol.2010.84. Nat Rev Urol. 2010. PMID: 20616795

9

The therapy of kidney cancer with biomolecular drugs.

Di Lorenzo G, Buonerba C, Biglietto M, Scognamiglio F, Chiurazzi B, Riccardi F, Cartenì G. Di Lorenzo G, et al. Among authors: buonerba c. Cancer Treat Rev. 2010 Nov;36 Suppl 3:S16-20. doi: 10.1016/S0305-7372(10)70015-3. Cancer Treat Rev. 2010. PMID: 21129605 Review.

10

Sipuleucel-T for prostate cancer: the immunotherapy era has commenced.

Buonerba C, Ferro M, Di Lorenzo G. Buonerba C, et al. Expert Rev Anticancer Ther. 2011 Jan;11(1):25-8. doi: 10.1586/era.10.180. Expert Rev Anticancer Ther. 2011. PMID: 21166508 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

191 results

Search Page

Filters